IP Library Patent Application 15613431
Patent Application
App. No. 15/613,431

Morphinan Derivatives for the Treatment of Drug Overdose

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/613,431
Abstract

The instant application relates to morphinan derivatives of Formula I with sustained effectiveness in treating drug toxicity and overdose:

Claims (23)

1 . A method of treating an opioid toxicity or overdose in a subject in need thereof comprising administrating a first opioid receptor antagonist followed by a compound of Formula I:

or a pharmaceutically acceptable salt, ester or prodrug thereof wherein;

R 1 is —(CH 2 ) n -c-C 3 H 5 , —(CH 2 ) n -c-C 4 H 7 , —(CH 2 ) n -c-C 5 H 9 , —(CH 2 ) n —CH═CH 2 or —(CH 2 ) n —CH═C(CH 3 ) 2 wherein n is independently 0, 1, 2 or 3;

R 2 is —CONH 2 or —CSNH 2 ;

R 3 and R 4 are independently H, —OH or together R 3 and R 4 form an —O— or —S— group;

R 5 is H or C 1 -C 8 alkyl; and

R 6 and R 7 are independently H, —OH, OCH 3 or together R 6 and R 7 form a ═O or ═CH 2 group.

2 . The method according to claim 1 , wherein said first opioid receptor antagonist is naloxone.

3 . The method according to any one of claim 1 , wherein said drug toxicity or overdose is resulting from opioid administration to a non-dependent patient.

4 . The method according to claim 3 , wherein said subject is an opioid experienced non-dependent opioid user.

5 . The method according to claim 2 , wherein said administration of compound of Formula I is preceded by said naloxone administration.

6 . The method according to claim 5 , wherein said naloxone administration reduces symptoms of overdose or toxicity prior to administration of compounds of Formula I.

7 . The method according to any one of claim 1 , wherein said compound of Formula I is administered in a daily dose of about 3 to about 20 mg/day.

8 . The method according to claim 7 , wherein said daily dose is about 10 mg/day.

9 . The method according to claim 1 , wherein administration of a compound of Formula I reduces symptoms of opioid toxicity or overdose over a period of at least about 15 to about 30 minutes.

10 . The method according to claim 9 , wherein symptoms of opioid toxicity or overdose are reduced for a period of at least one hour.

11 . The method according to claim 9 , wherein symptoms of opioid toxicity or overdose are reduced for a period of at least two hours.

12 . The method according to claim 9 , wherein symptoms of opioid toxicity or overdose are reduced for a period of at least three hours.

13 . The method according to claim 9 , wherein symptoms of opioid toxicity or overdose are reduced for a period of at least four hours.

14 . The method according to claim 9 , wherein symptoms of opioid toxicity or overdose are reduced for a period of at least eight hours.

15 . The method according to any one of claim 9 , wherein said administration comprises about 3 mg to about 20 mg of a compound of Formula I.

16 . The method according to any one of claim 9 , wherein said symptoms of overdose is selected from decreased respiratory rate, decreased respiratory depth, apnea, comotosis, hypoxia, delirium hypotension, bradycardia, decreased body temperature, urinary retention and pupil miosis.

17 . The method according to claim 2 , wherein naloxone is administered concurrently with a compound of Formula I.

Assignments (1)
SECURITY INTEREST Recorded Feb 7, 2018
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 044858/0280 →